World's Biggest Biotech Takes on Cancer

This episode of The Motley Fool's Market Checkup drills down on the days hottest headlines, and takes a look at two favorite health-care-focused dividend stocks. Market Checkup gives a full examination of the recent regulatory action around a new blood cancer drug, a European orphan drug approval, and why a big pharma shockingly stopped the FDA from reviewing its newest diabetes drug.

In this video, health-care analysts David Williamson and Max Macaluso discuss Gilead's (NASDAQ: GILD  )  new drug application for idelalisib, which treats Non-Hodgkin's Lymphoma. Watch and find out how it stacks up against its competition, its sales potential, and its overall importance to the big biotech.

Stocks for a wealthy retirement
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.

Follow David on Twitter: @MotleyDavid.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2642491, ~/Articles/ArticleHandler.aspx, 4/18/2014 7:47:27 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement